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elementa b s t r a c t
Anti-Müllerian hormone (AMH) has both paracrine and hormonal actions that occur at different
AMH concentrations, and in cells with different densities of its speciﬁc receptor (Amhr2). This diver-
sity is not explained by canonical AMH signaling. We report that Amhr2 has two splice variants:
Amhr2D2 (AMH binding site) and Amhr2D9/10 (kinase domain). Both spliced variants inhibit
AMH signaling in a reporter assay. The mRNA for the spliced variants was relatively less abundant
than Amhr2 mRNA in all tissues. This suggests that the physiological function(s) of the receptor vari-
ants may be restricted to speciﬁc cellular/subcellular sites and/or to the transport of AMH.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Anti-Müllerian hormone (AMH, Müllerian inhibiting substance)
is a gonadal secretion, whose classical function is to trigger the re-
moval of the uterine precursor in male embryos [1]. For many dec-
ades, AMH was thought to have a single function, and so it has not
been extensively studied. However, AMH is also a paracrine regu-
lator of the testes [2] and in mice, contributes to the male bias in
the nervous system [3–5] and the lungs [6]. In humans, boys have
very high levels of AMH [7,8], that correlate with their rate of mat-
uration [9], suggesting that plasma AMH is also a regulator of hu-
man male development. As boys enter puberty, their levels of AMH
drop, whereas the ovaries of pubescent girls begin to synthesize
AMH [7,10]. Consequently, young men and women have similar
levels of AMH. The adult plasma levels of AMH are ten fold lower
than those of boys [7,8,10], but are still sufﬁcient to produce signif-
icant effects in some AMH-sensitive cell lines [11–15]. The physio-
logical function(s) of plasma AMH in adults are unknown, althoughregulation of cardiovascular function [16,17] and insulin-resis-
tance are emerging as possibilities [18].
The canonical mechanism for AMH signaling does not explain
why AMH can have both endocrine and paracrine actions. AMH
is a member of the TGFb superfamily, which signals through a
receptor complex consisting of type 1and type 2 receptors
[19,20]. The formation of the AMH signaling complex is initiated
by the binding of AMH to AMHR2, which then recruits a type 1
receptor [21]. The Kd of AMHR2 for AMH is 2–3 nM [22,23]. This
is consistent with the levels of AMH in gonadal ﬂuids, which can
exceed 7 nM [24]. However, the low median level of AMH in the
blood of young adults (20 pM [8,10]) and boys (1.0 nM, [9]) should
only produce trace or minimal receptor activation. The existence of
strong responses to plasma levels of AMH [3,4] is thus consistent
with AMH having additional ways of signaling.
Curiously, the abundance of Amhr2 mRNA in the testes is more
typical of a house-keeping gene than of a signaling receptor subunit
[3] (see also [15,25]). While the level of Amhr2 mRNA in neurons is
high compared to other receptors, the amount of mRNA and protein
is less than10%of that in the testes [3]. This is counterintuitive as the
cells with the lower density of receptor respond to lower levels of
AMH (c.f. [20–24]). This could be explained if a proportion of the
AMHR2 in the gonadswasunable to signal. A splice variant of Amhr2
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expressionpatternhavenotbeenexamined.Wereporthere that rats
and mice express two alternatively spliced variants of Amhr2, both
of which antagonize classical AMH signaling in a reporter assay.
2. Results and discussion
2.1. Amhr2 has two splice variants
cDNA prepared from mRNAs from the testes of 12.5 day mouse
fetuses, adult mice and adult rats were ampliﬁed by PCR, using
primers (Table S1) that spanned either the 50 ligand binding domain
or the 30 kinase domain (Fig. 1).With the 50 primers, two bandswere
detected with sizes that corresponded to the full length Amhr2 and
an exon 2 deﬁcient amplicon (Amhr2D2) (Fig. 1A). Similarly, with
the 30 primers, 2 bands corresponding to Amhr2 and an exon 9,10-
deﬁcient amplicon (Amhr2D9/10) were present (Fig. 1A). Variants
lacking either exon 9 alone or exon 10 alone were not detected.
The existence of the complete encoded receptor and the two vari-
ants was then conﬁrmed using primers that uniquely detected
Amhr2, Amhr2D2 or Amhr2D9/10 (Table S1, Fig. 1B). The bands
from all primer sets were isolated and sequenced, conﬁrming their
identities (Genebank KC920726, KC920727). The Amhr2D2 lacks
part of the AMH binding site, whereas the Amhr2D9/10 lacks part
of the intracellular kinase domain (Fig. 1C).
2.2. Tissue-speciﬁc expression
The levels of Amhr2 were examined in various mouse tissues by
real-time RT-PCR, and normalized to either Gapdh and Hprt.Fig. 1. There are two splice variants of the Amhr2. (A) mRNA was extracted from
the testes or various parts of the brains of adult mice (striatum, cerebellum (cereb)
and choroid plexus (Chor. Pl.) and cDNA prepared. One abundant and one minor
band were detected in the RT+ samples when the exon 1–3 region was ampliﬁed
(Amhr2 & Amhr2D2) and also when the exon 8–11 region was ampliﬁed (Amhr2 &
Amhr2D9/10), using the primers documented in Table S1. RT samples showed no
products. The identity of the bands was conﬁrmed by sequencing, after extraction.
(B) Samples of testes were examined using primers that were speciﬁc to Amhr2,
Amhr2D2 or Amhr2D9/10, using the primers documented in Table S1. No bands
were observed in the RT samples, with the identity of the bands conﬁrmed by
sequencing. (C) Schematic illustration of the protein variants of Amhr2. The exon
and intron structure of the gene is illustrated, with the putative structure of the
proteins outlined below. The Amhr2 protein domains are based on UniProtKB/
Swiss-Prot (http://www.uniprot.org/uniprot/Q8K592).Amhr2 mRNA was most abundant in the testes, with a level
288 ± 3 (n = 5) times that present in the brain. Amhr2 mRNA was
also present in the lung and adrenal glands at levels that were sim-
ilar to those in the brain (62 ± 1% and 150 ± 10%, respectively, n = 5)
(Fig. 2). Only trace levels (within 1 CT of the cut off) of Amhr2 were
present in the heart, aorta and abdominal fat, with no Amhr2 being
detectable in the spleen, kidney or bone.
The level of Amhr2D9/10 mRNA in the testes and the brain was
approximately 5% of the level of Amhr2 mRNA, with Amhr2D2
being present at lower levels, when measured by real-time RT-PCR.
All of the TGFb receptors except AMHR2 are known to bind mul-
tiple ligands. Amhr2D2 has an altered ligand-binding site, which
raised the possibility that it has functions unrelated to AMH. We
therefore examined whether Amhr2D2 or Amhr2D9/10 was ex-
pressed in those tissues that showed no or minimal expression of
Amhr2. None contained detectable levels of Amhr2D2 or
Amhr2D9/10.
2.3. Reporter assay for AMH signaling
A reporter assay for AMH signaling was developed to test
whether the Amhr2 splice variants are dominant negative recep-
tors. The type I receptors that complex with AMHR2 are shared
with BMPRII [19,27], thus enabling a BMP luciferase assay to be
adapted to report AMH signaling (see also [28]). A human AMH-
sensitive [29] prostate cell line, DU145 [30], was used for this pur-
pose. It expresses Acvr1 (ALK2), Bmpr1a (ALK3) and low levels of
Bmpr1b (ALK6) (Fig. S1), which are the type 1 receptors for AMH
and BMP signaling [27]. DU145 cells were transiently transfected
with two plasmids: the ﬁrst contained the BMP-responsive ele-
ments from the Id1 promoter fused to a luciferase reporter gene
[31,32], with the second being a Renilla reniformis luciferase
(phRL-SV40) plasmid to control for variation in transfection efﬁ-
ciency [33]. The proliferation of the DU145 cells was not affected
by either AMH or the transfection of the cells with Amhr2D2 or
Amhr2D9/10 (Fig. S2).
2.4. AMHR2 splice variants inhibit AMH signaling
DU145 cells responded to AMH with a low level of ﬁreﬂy lucif-
erase expression. This expression was increased in a dose-depen-
dent manner when the cells were transfected with Amhr2
(Fig. 3). This indicates that the levels of AMHR2 can inﬂuence the
strength of a cell’s response to AMH. Transfection with the control
vector had no effect. In contrast, transfection with either Amhr2D2Fig. 2. Abundance of Amhr2 and its splice variants in tissues. mRNA was extracted
from adult murine tissues and the levels of Amhr2 transcripts measured by real-
time PCR, and normalized relative to Gapdh and Hprt. The bars are the
mean + standard error of the mean of tissues from ﬁve mice. The heart, aorta,
abdominal fat, spleen, kidney or bone had either trace or no Amhr2, and had
undetectable levels of Amhr2D2 and Amhr2D9/10.
Fig. 3. Transfection with an Amhr2 plasmid increases BRE-reporter activity. DU145
cells were transfected with the indicated amounts of Amhr2 expression plasmid
plus varying amounts of pcDNA control plasmid to give a total of 2 lg of plasmid for
all cells. The medium included 100 ng/ml of AMH (4.3 nM). The activity ratio of
ﬁreﬂy luciferase (from the BRE reporter) to Renilla reniformis luciferase (from the
transfection control vector) was calculated for each condition. The points represent
the mean ± the standard error of the mean of 9 wells.
Fig. 5. The Amhr2 splice variants antagonize equivalent amounts of Amhr2. DU145
cells were transfected with 1 lg/well of control vector (ctrl, green bars), Amhr2D2
(D2, brown bars) or Amhr2D9/10 (D9/10, blue bars) and1 lg of Amhr2, (BRE)2-Luc
and phRL-SV40. The cells were incubated in either 3 ng/ml (0.13 nM, lightly-colored
bars) or 100 ng/ml (4.3 nM, dark colored bars) of AMH, representing plasma and
gonadal levels respectively. The ratio of the ﬁreﬂy luciferase to the Renilla reniformis
luciferase calculated for each condition was normalized to the ratio obtained after
transfection of the Amhr2 (1.0). The bars represent the mean ± the standard error of
the mean of 8 wells obtained from 2 cultures. ⁄1 and ⁄2: signiﬁcantly different to the
corresponding R2 + ctrl wells, P < 0.0001 and P = 0.008 respectively, Student’s t-test.
⁄3 and ⁄4: the 0.13 and 4.3 nM wells were signiﬁcantly different to each other,
P < 0.0001 and P = 0.008 respectively, Student’s t-test.
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ﬁreﬂy luciferase to undetectable levels, indicating that the endog-
enous AMHR2 activity had been silenced (Fig. 4).
The potency of the splice variants was then examined by co-
transfecting them with the non-spliced Amhr2. Under this circum-
stance, the reporter activity associated with AMHR2 was reduced
by approximately 30% when co-transfected with an equal amount
of plasmid containing either Amhr2D2 or Amhr2D9/10 (Fig. 5). The
extent of the inhibition was slightly greater with plasma-like levels
of AMH (3 ng/ml, 0.13 nM) than with gonadal-like levels (100 ng/
ml, 4.3 nM). This is incompatible with Amhr2D2 and Amhr2D9/
10 being constitutive regulators of AMH signaling in the gonads,
as both splice variants are less abundant than Amhr2.
There are some alternative possibilities for the physiological
functions of the splice variants. First, the splice variants could be
dominant-negative inhibitors in vivo, if their expression is re-
stricted to a speciﬁc physiological state of a cell. For example,
sperm production is initiated by the mitotic proliferation of sper-
matogonia that then remains quiescent for an invariant number
of days. During this period of quiescence, the daughter cells under-
go meiosis and differentiate into sperm. This process is spatially
asynchronous within the seminiferous tubules, and all stages of
sperm production are present in the testes at all times [34]. Hence,
the AMHR2 splice variants may be transiently present at high lev-
els in a minority of cells to regulate a particular stage of sperm
production.Fig. 4. The Amhr2 splice variants inhibit endogenous AMH signaling. DU145 cells
were transfected with a control (ctrl, gray bar), Amhr2 (R2, dark green bar),
Amhr2D2 (D2, brown bar) or Amhr2D9/10 (D9/10, blue bar) plasmid, along with
(BRE)2-Luc and phRL-SV40. The ratio of the ﬁreﬂy luciferase to the Renilla reniformis
luciferase calculated for each condition was normalized to the ratio obtained after
transfection of the Amhr2 (1.0). The ratio was equal to zero after transfection of D2
for all 9 wells. ⁄1 signiﬁcantly different from control wells, P < 0.0001, Student’s t-
test. ⁄2 signiﬁcantly different from control wells, P = 0.0005, Student’s t-test.Second, some truncated receptors from other cytokine families
have ligand-independent signaling. For example, the complex
microanatomy of some neurons is shaped by kinase-deﬁcient vari-
ants of neutrophin Trk receptors [35,36]. These modiﬁed receptors
act at speciﬁc subcellular sites, through a mechanism that appears
to involved intracellular interactions outside of the kinase domain
[35,36]. By analogy, the AMHR2 variants could have site-speciﬁc
effects on neurons and/or gonadal cells, particularly if they do
not co-localize with AMHR2.
Third, non-signaling variants of some cytokine receptors are in-
volved in the transport of ligands. This commonly involves inter-
nalization by non-target cells, to restrict local diffusion of the
cytokine [37]. Receptor mediated transport is also important for
the translocation of protein hormones from the blood, with both
signaling and non-signaling receptors being involved [35]. This
may be particularly relevant to the actions of gonadal AMH on
the brain, because of the blood–brain barrier. AMHR2D9/10 could
thus be an AMH transporter.
In summary, the testes and the brain express splice variants of
the Amhr2 that are dominant negative inhibitors of AMH signaling,
when present in excess. These receptors may be involved in phys-
iological processes that are restricted to speciﬁc cellular/subcellu-
lar sites or to the transport of AMH.
3. Methods
3.1. Animals
C57BL/6 mice and Wistar rats were bred at the University of
Otago [38]. Mouse embryos were obtained from timed pregnan-
cies, with the day of the vaginal plug being designated as E0. All
procedures were approved by the University of Otago’s Animal
Ethics Committee.
3.2. RT-PCR
Tissues from 12.5-day-old mouse fetuses, adult mice and rats
were snap frozen in liquid nitrogen, and stored at 80 C for up
to 2 days. Total RNA fractions were isolated with TRIzol reagent
(Invitrogen), with the integrity of the samples assessed using form-
aldehyde denaturing agarose gels. The isolated RNA fractions were
treated with DNase I (Promega) and the RNA concentration as-
sessed using a nanodrop ND-1000 spectrophotometer (NanoDrop
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RNase H (rats, embryos) or Superscript III reverse transcriptase
(adult mice) (Invitrogen) and oligo-d(T)15 as the primer. RT-PCR
and real-time RT-PCR were as previously described [39], using
primers listed in Table S1. Real-time RT-PCR was used for quanti-
tative measurement of mRNA abundance, with the use of RT-PCR
limited to detecting the existence of the spliced variants.
3.3. Cell culture
DU145 cells (American Type Culture Collection cell bank) were
maintained at 37 C, 5% CO2 in Roswell Park Memorial Institute
medium 1640 containing 2 mM L-glutamine (Gibco) and supple-
mented with 10 mM HEPES, 1 mM sodium pyruvate, 25 mM glu-
cose, 17.85 mM sodium bicarbonate (RPMI). The medium for the
stock cultures contained 10% fetal bovine serum (Gibco). DU145
cells express Amhr2, Acvr1 (ALK2), Bmpr1a (ALK3) and low levels
of Bmpr1b (ALK6), and respond to AMH (veriﬁed in our studies
by PCR analysis).
3.4. Amhr2 expression vectors
The Amhr2, Amhr2D2 and Amhr2D9/10 sequences were ampli-
ﬁed from mouse testes cDNA using the primers listed in Table S1.
Primers Amhr2-vecF and Amhr2-R were used to amplify Amhr2.
Amhr2D2 with deletion of exon 2 was produced using primers
Amhr2D2-vecF and Amhr2-R. Amhr2D9/10 was ampliﬁed in two
stages. A 333 bp fragment with exons 9 and 10 deleted was ampli-
ﬁed with primers Amhr2-R and Amhr2D9-vecF and used as a meg-
aprimer in a second reaction along with primer Amhr2-vecF to
produce the complete Amhr2D9/10. The PCR products were cloned
into the vector pcDNA3.1(+) (Invitrogen) using restriction enzymes
BamHI and EcoRI (Roche Applied Science) and standard cloning
techniques. All recombinant plasmids were veriﬁed by sequencing.
3.5. Luciferase reporter assay
DU145 cells were transiently transfected at the time of seeding
(100000 cells per well, 24 well-plate) with 1 lg of either Amhr2,
an Amhr2 isoform or control pcDNA vector, 200 ng of (BRE)2-Luc
reporter vector and 100 ng of phRL-SV40 (promega) transfection
control vector using the FuGENE 6 transfection reagent in a 3 lL
FuGENE 6 per 1 lg of DNA ratio (Roche), according to the manufac-
turer’s instructions. The cells were maintained in RPMI supple-
mented with 5% FBS for 48 h. rhAMH (R&D Systems, mature C-
terminal, 1737-MS-010) or vehicle was added to the medium
24 h after transfection. The ﬁnal concentration of AMH was
100 ng/ml (4.3 nM), unless otherwise stated. Each condition was
examined in triplicate, with each experiment replicated 3 times.
The luciferase activity was detected using the Dual-Luciferase re-
porter assay system (Promega). An Optima (BMG Labtech) plate
reader at 30 C was used to minimize variation between samples.
The (BRE)2-luc vector was kindly donated by Dr. Peter ten Dijke
(The Netherlands Cancer Institute, Amsterdam).Conﬂict of interest
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